Right to Try Clarification Act

Bill: 117-hr-8440
Sponsor: full_name: Rep. Blumenauer, Earl [D-OR-3]
Introduced: 2022-07-20
Policy area: Health
Latest action: action_date: 2022-11-01
text: Referred to the Subcommittee on Crime, Terrorism, and Homeland Security.

Summaries:
action_date: 2022-07-20
action_desc: Introduced in House
text: <p><b>Right to Try Clarification Act</b></p> <p>This bill specifies that investigational drugs that are provided directly to individuals from manufacturers without the need for federal regulatory approval (i.e., via the Right to Try pathway) are exempt from restrictions that would otherwise apply under the Controlled Substances Act (e.g., restrictions on the use or possession of schedule I controlled substances).</p>

tv_txt: I 117th CONGRESS 2d Session H. R. 8440 IN THE HOUSE OF REPRESENTATIVES July 20, 2022 Mr. Blumenauer (for himself, Ms. Mace , Ms. Dean , Mr. Biggs , and Mr. Correa ) introduced the following bill; which was referred to the Committee on Energy and Commerce , and in addition to the Committee on the Judiciary , for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned A BILL To clarify that the Federal Right to Try law applies to schedule I substances for which a phase I clinical trial has been completed and to provide access for eligible patients to such substances pursuant to the Federal Right to Try law.

1. Short title This Act may be cited as the Right to Try Clarification Act . 2. Findings Congress finds as follows: (1) The Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017 ( Public Law 115–176 ) was enacted in 2018. (2) Section 561B of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360bbb–0a ), as added by the Act described in paragraph (1) (referred to in this section as the Federal Right to Try law ), does not exclude from the application of such law schedule I substances for which a phase I clinical trial has been completed. (3) Multiple schedule I drugs have progressed through phase I clinical trials and have been designated by the Food and Drug Administration as breakthrough therapies under section 506 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 356 ) because of preliminary clinical evidence indicating that such drugs demonstrate substantial improvement over existing therapies, but eligible patients have not been permitted access to these drugs pursuant to the Federal Right to Try law. 3. Amendment to Federal Right to Try law Section 561B(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360bbb–0a(b)) is amended by inserting any provision of the Controlled Substances Act ( 21 U.S.C. 801 et seq. ) that prohibits the unauthorized use, possession, distribution, dispensation, or transportation of an eligible investigational drug, before and parts .